Litcius/Paper detail

Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis

Roberto Iacovelli, Chiara Ciccarese, Gaetano Facchini, Michèle Milella, Federica Urbano, Umberto Basso, Ugo De Giorgi, Roberto Sabbatini, Daniele Santini, Rossana Berardi, Matteo Santoni, Sergio Bracarda, Francesco Massari, Cristina Masini, Michele De Tursi, Riccardo Ricotta, Sebastiano Buti, Fable Zustovich, Pierangela Sepe, Sabrina Rossetti, Marco Maruzzo, Enrico Cortesi, Giampaolo Tortora, Giuseppe Procopio

2020Targeted Oncology39 citationsDOIOpen Access PDF

Topics & Concepts

CabozantinibMedicineNivolumabRenal cell carcinomaOncologyInternal medicineClinical endpointProgressive diseaseImmunotherapyAxitinibImmune checkpointKidney cancerResponse Evaluation Criteria in Solid TumorsSurgeryCancerDiseaseClinical trialSunitinibRenal cell carcinoma treatmentCancer Immunotherapy and BiomarkersFerroptosis and cancer prognosis
Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis | Litcius